Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin-Antibody Conjugate

Overview

Journal Mol Cancer Ther

Date 2017 Dec 15

PMID 29237807

Citations 15

Authors

Tadanobu Nagaya

Alexander P Gorka

Roger R Nani

Shuhei Okuyama

Fusa Ogata

Yasuhiro Maruoka

Peter L Choyke

Martin J Schnermann

Hisataka Kobayashi

Affiliations

Soon will be listed here.

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that uses an antibody-photoabsorber conjugate (APC). However, the effect of NIR-PIT can be enhanced when combined with other therapies. NIR photocaging groups, based on the heptamethine cyanine scaffold, have been developed to release bioactive molecules near targets after exposure to light. Here, we investigated the combination of NIR-PIT using panitumumab-IR700 (pan-IR700) and the NIR-releasing compound, CyEt-panitumumab-duocarmycin (CyEt-Pan-Duo). Both pan-IR700 and CyEt-Pan-Duo showed specific binding to the EGFR-expressing MDAMB468 cell line In studies, additional injection of CyEt-Pan-Duo immediately after NIR light exposure resulted in high tumor accumulation and high tumor-background ratio. To evaluate the effects of combination therapy , tumor-bearing mice were separated into 4 groups: (i) control, (ii NIR-PIT, (iii) NIR-release, (iv) combination of NIR-PIT and NIR-release. Tumor growth was significantly inhibited in all treatment groups compared with the control group ( < 0.05), and significantly prolonged survival was achieved ( < 0.05 vs. control). The greatest therapeutic effect was shown with NIR-PIT and NIR-release combination therapy. In conclusion, combination therapy of NIR-PIT and NIR-release enhanced the therapeutic effects compared with either NIR-PIT or NIR-release therapy alone. .

Citing Articles

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs.

Morcos A, Jung Y, Galvan Bustillos J, Fuller R, Caba Molina D, Bertucci A Cancers (Basel). 2024; 16(19).

PMID: 39409913 PMC: 11475672. DOI: 10.3390/cancers16193293.

Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models.

Fukushima H, Furusawa A, Takao S, Thankarajan E, Luciano M, Usama S Oncoimmunology. 2024; 13(1):2370544.

PMID: 38915782 PMC: 11195482. DOI: 10.1080/2162402X.2024.2370544.

Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.

Monaco H, Yokomizo S, Choi H, Kashiwagi S View (Beijing). 2023; 3(3).

PMID: 37448778 PMC: 10343942. DOI: 10.1002/VIW.20200110.

Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers.

Cui Y, Xu Y, Li Y, Sun Y, Hu J, Jia J Technol Cancer Res Treat. 2023; 22:15330338221145992.

PMID: 36734039 PMC: 9903039. DOI: 10.1177/15330338221145992.

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.

Wei D, Qi J, Hamblin M, Wen X, Jiang X, Yang H Theranostics. 2022; 12(16):7108-7131.

PMID: 36276636 PMC: 9576624. DOI: 10.7150/thno.74820.

References

Luo S, Zhang E, Su Y, Cheng T, Shi C . A review of NIR dyes in cancer targeting and imaging. Biomaterials. 2011; 32(29):7127-38. DOI: 10.1016/j.biomaterials.2011.06.024. View

Tsai M, Aki R, Amoh Y, Hoffman R, Katsuoka K, Kimura H . GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. Anticancer Res. 2010; 30(9):3291-4. View

Weinstein J, van Osdol W . Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 1992; 52(9 Suppl):2747s-2751s. View

Juweid M, Neumann R, Paik C, Sato J, van Osdol W, Weinstein J . Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992; 52(19):5144-53. View

Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke P, Kobayashi H . Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012; 12:345. PMC: 3502522. DOI: 10.1186/1471-2407-12-345. View

van Osdol W, Fujimori K, Weinstein J . An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 1991; 51(18):4776-84. View

Momiyama M, Suetsugu A, Kimura H, Kishimoto H, Aki R, Yamada A . Fluorescent proteins enhance UVC PDT of cancer cells. Anticancer Res. 2012; 32(10):4327-30. View

Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I . Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol Oncol. 2014; 8(3):620-32. PMC: 4004687. DOI: 10.1016/j.molonc.2014.01.006. View

Gorka A, Nani R, Schnermann M . Cyanine polyene reactivity: scope and biomedical applications. Org Biomol Chem. 2015; 13(28):7584-98. PMC: 7780248. DOI: 10.1039/c5ob00788g. View

10.

Sano K, Nakajima T, Choyke P, Kobayashi H . Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano. 2012; 7(1):717-24. PMC: 3586604. DOI: 10.1021/nn305011p. View

11.

Pass H, Temeck B, Kranda K, Thomas G, Russo A, Smith P . Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1998; 4(8):628-33. DOI: 10.1007/BF02303746. View

12.

Weissleder R . A clearer vision for in vivo imaging. Nat Biotechnol. 2001; 19(4):316-7. DOI: 10.1038/86684. View

13.

Thurber G, Schmidt M, Wittrup K . Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008; 60(12):1421-34. PMC: 2820307. DOI: 10.1016/j.addr.2008.04.012. View

14.

Momiyama M, Suetsugu A, Kimura H, Kishimoto H, Aki R, Yamada A . Imaging the efficacy of UVC irradiation on superficial brain tumors and metastasis in live mice at the subcellular level. J Cell Biochem. 2012; 114(2):428-34. DOI: 10.1002/jcb.24381. View

15.

Graff C, Wittrup K . Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003; 63(6):1288-96. View

16.

Nagaya T, Sato K, Harada T, Nakamura Y, Choyke P, Kobayashi H . Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS One. 2015; 10(8):e0136829. PMC: 4552472. DOI: 10.1371/journal.pone.0136829. View

17.

Hoffman R . Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015; 15(8):451-2. DOI: 10.1038/nrc3972. View

18.

Nani R, Gorka A, Nagaya T, Yamamoto T, Ivanic J, Kobayashi H . Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent Sci. 2017; 3(4):329-337. PMC: 5408340. DOI: 10.1021/acscentsci.7b00026. View

19.

Gorka A, Schnermann M . Harnessing cyanine photooxidation: from slowing photobleaching to near-IR uncaging. Curr Opin Chem Biol. 2016; 33:117-25. PMC: 7383357. DOI: 10.1016/j.cbpa.2016.05.022. View

20.

Levitus M, Ranjit S . Cyanine dyes in biophysical research: the photophysics of polymethine fluorescent dyes in biomolecular environments. Q Rev Biophys. 2010; 44(1):123-51. DOI: 10.1017/S0033583510000247. View